01 · CAPABILITY

Specialty Pharmaceuticals

Differentiated therapies developed on the 505(b)(2) pathway, reformulations and combinations that leverage existing safety data to reach patients faster, with a clear clinical rationale behind every program.

  • MT-01, our lead 505(b)(2) combination program, currently in stability studies with first data expected in 2027.
  • A second innovation program in oncology supportive care, in ideation and early formulation.
  • Regulatory-led design, submission strategy is defined before formulation work begins.
505(b)(2) · NDA Reformulation Combination
Discuss a specialty program
01
Lead program
MT-01, a 505(b)(2) combination reformulation in stability studies.
02 · CAPABILITY

Generics

A pipeline of bioequivalent generic products across sterile injectables, oral liquids, and oral solids, developed with our R&D partners and manufactured through an established European network.

  • Sterile injectables and liquids, produced at dedicated European capacity built for these forms.
  • Oral solids and solutions spanning cardiology, diabetology, pain, dermatology, ophthalmology, and neurology.
  • Portfolio in selection and development, first ANDA dossiers are being prepared.
Generics · ANDA Sterile Injectables Oral Solids & Liquids
Explore a generics partnership
02
Manufacturing
Dedicated European capacity for sterile injectables and liquids.
03 · CAPABILITY

Consumer Health

Our first consumer health range, color cosmetics and nutraceuticals developed to pharmaceutical quality standards and built for distribution across regulated and emerging markets.

  • 20 color cosmetic formulations in development, spanning core categories.
  • 10 nutraceutical products covering everyday wellness and targeted supplementation.
  • Distribution-ready, formulated, packaged, and documented for multi-market launch.
Color Cosmetics Nutraceuticals Multi-market
Discuss distribution
03
In development
30 formulations, 20 color cosmetics and 10 nutraceuticals.
04 · CAPABILITY

Development & Consulting

We do for other companies what we do for our own pipeline, regulatory strategy, formulation development, and the work of getting a product into a new market, without them building the function in-house.

  • Regulatory strategy, pathway selection, agency engagement, and submission planning.
  • Formulation & development, from pre-formulation through analytical method development and scale-up.
  • Market access & territory expansion, dossier adaptation, local registration, and distribution setup for new geographies.
Regulatory Formulation Market Access
Request an engagement
04
For partners
Regulatory, formulation, and market-access support, on demand.
05 · CAPABILITY

CDMO & Manufacturing

Access to dedicated European manufacturing capacity and a vetted network of development, manufacturing, and distribution partners across Europe, India, and emerging markets.

  • Sterile injectables and liquids, a dedicated European manufacturing base for these forms.
  • Solid dose and semi-solids through EU-GMP and WHO-GMP partner sites.
  • Distribution reach into EMEA, India, and selected emerging markets through commercial partners.
EU-GMP WHO-GMP Distribution Network
Explore manufacturing access
05
Network
European and Indian partners across development, manufacturing, and distribution.
Pipeline

Programs in development

A snapshot of our active programs. Product and indication-specific details are shared with qualified partners under confidentiality.

Program
Category
Pathway
Stage
MT-01
Combination reformulation
Specialty, 505(b)(2)
NDA, 505(b)(2)
ConceptFormulationStabilityClinicalNDA
MT-02
Oncology supportive care (CINV)
Specialty, 505(b)(2)
NDA, 505(b)(2)
ConceptFormulationStabilityClinicalNDA
Generic Portfolio
Injectables, liquids, oral solids
Generics
ANDA
SelectionDevelopmentBioequivalenceDossierFiling
Consumer Health Range
20 color cosmetics, 10 nutraceuticals
Consumer Health
Cosmetic / Supplement
ConceptFormulationStabilityPackagingLaunch

Program names are internal designations. Stages are indicative and subject to change.

Regulatory Pathways

Literate across every framework we touch

Our platform is built to navigate the range of pathways relevant to our products, without compromise on scientific or procedural rigor.

Pharma · NDA
505(b)(2)

Hybrid NDA pathway that leverages existing safety data for reformulated, repurposed, or combination drug products.

Pharma · Generic
ANDA

Abbreviated new drug application for bioequivalent generic therapies referencing an approved innovator product.

Manufacturing
EU-GMP & WHO-GMP

Good manufacturing practice standards, both European and WHO, governing our sterile, liquid, and solid-dose partner sites across regulated and emerging markets.

Consumer Health
Cosmetic & Supplement

Cosmetic (MoCRA / EU CPR) and dietary supplement frameworks governing our consumer health range across markets.